Ken Griffin Kura Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$18.57 - $23.23 $230,268 - $288,052	-12,400 Reduced 56.11%	9,700 $189,000
Q2 2024 Aug 14, 2024	BUY	$17.53 - $22.98 $215,619 - $282,654	12,300 Added 125.51%	22,100 $455,000
Q1 2024 May 15, 2024	BUY	$13.42 - $23.53 $21,472 - $37,648	1,600 Added 19.51%	9,800 $209,000
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $15,918 - $30,198	-2,100 Reduced 20.39%	8,200 $117,000
Q3 2023 Nov 14, 2023	SELL	$8.44 - $11.86 $44,732 - $62,858	-5,300 Reduced 33.97%	10,300 $93,000
Q2 2023 Aug 14, 2023	BUY	$9.62 - $13.99 $109,667 - $159,486	11,400 Added 271.43%	15,600 $165,000
Q1 2023 May 15, 2023	SELL	$10.71 - $14.6 $25,704 - $35,040	-2,400 Reduced 36.36%	4,200 $51,000
Q4 2022 Feb 14, 2023	SELL	$11.23 - $16.9 $713,105 - $1.07 Million	-63,500 Reduced 90.58%	6,600 $81,000
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $10,809 - $17,505	900 Added 1.3%	70,100 $958,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $1.06B
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.